1-8 of 8
Véronique Diéras
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)

Shannon L. Puhalla, Véronique Diéras, Banu K. Arun, Bella Kaufman, Hans Wildiers, Hyo S. Han, Jean-Pierre Ayoub, Vered Stearns, Yuan Yuan, Teresa Helsten, Bridget Riley-Gillis, Erin Murphy, Madan G. Kundu, Meijing Wu, David Maag, Christine K. Ratajczak, Cyril Y. Ramathal, Michael Friedlander
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 4983–4993.
https://doi.org/10.1158/1078-0432.CCR-21-0748
Published: 15 September 2021
View article titled, Relevance of Platinum-free Interval and <em>BRCA</em> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<em>BRCA</em> Advanced Breast Cancer (BROCADE3 Crossover)
Open the PDF for Relevance of Platinum-free Interval and <em>BRCA</em> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<em>BRCA</em> Advanced Breast Cancer (BROCADE3 Crossover) in another window
Includes: Supplementary data
Journal Articles

Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer

Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1582.
https://doi.org/10.1158/1078-0432.CCR-21-0193
Published: 01 March 2021
View article titled, Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer
Open the PDF for Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer in another window
Journal Articles

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (20): 5310–5319.
https://doi.org/10.1158/1078-0432.CCR-20-1764
Published: 15 October 2020
View article titled, A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Open the PDF for A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer

Richard S. Finn, Yuan Liu, Zhou Zhu, Miguel Martin, Hope S. Rugo, Véronique Diéras, Seock-Ah Im, Karen A. Gelmon, Nadia Harbeck, Dongrui R. Lu, Eric Gauthier, Cynthia Huang Bartlett, Dennis J. Slamon
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 110–121.
https://doi.org/10.1158/1078-0432.CCR-19-0751
Published: 03 January 2020
View article titled, Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer
Open the PDF for Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortés, Véronique Diéras, Debra Patt, Hans Wildiers, Clifford A. Hudis, Joyce O'Shaughnessy, Esther Zamora, Denise A. Yardley, Martin Frenzel, Andrew Koustenis, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5218–5224.
https://doi.org/10.1158/1078-0432.CCR-17-0754
Published: 31 August 2017
View article titled, MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer
Open the PDF for MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, Veronique Dieras, Jan H.M. Schellens, Jean-Philippe Spano, Mark R. Middleton, Emiliano Calvo, Luiz Paz-Ares, James Larkin, Simon Pacey, Miro Venturi, Françoise Kraeber-Bodéré, Jean J.L. Tessier, Wilfried Ernst Erich Eberhardt, Michel Paques, Ernesto Guarin, Valerie Meresse, Jean-Charles Soria
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4251–4261.
https://doi.org/10.1158/1078-0432.CCR-14-0341
Published: 13 August 2014
View article titled, Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <em>RAS–RAF</em> Mutations
Open the PDF for Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <em>RAS–RAF</em> Mutations in another window
Includes: Supplementary data
Journal Articles

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

Gail D. Lewis Phillips, Carter T. Fields, Guangmin Li, Donald Dowbenko, Gabriele Schaefer, Kathy Miller, Fabrice Andre, Howard A. Burris, III, Kathy S. Albain, Nadia Harbeck, Veronique Dieras, Diana Crivellari, Liang Fang, Ellie Guardino, Steven R. Olsen, Lisa M. Crocker, Mark X. Sliwkowski
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (2): 456–468.
https://doi.org/10.1158/1078-0432.CCR-13-0358
Published: 16 January 2014
View article titled, Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Open the PDF for Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber-Bodéré, Veronique Dieras, Max E. Scheulen, Avinash Gupta, Vanesa Lopez-Valverde, Zhi-Xin Xu, Ruediger Rueger, Jean J.L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jan H.M. Schellens, Wilfried Ernst Erich Eberhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4794–4805.
https://doi.org/10.1158/1078-0432.CCR-12-0868
Published: 30 August 2012
View article titled, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data